Clinical Trial Detail

NCT ID NCT04429321
Title Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Pennsylvania
Indications

renal cell carcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.